C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment
WATERTOWN, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced the appointment of Owen Hughes to its board of directors.
- WATERTOWN, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced the appointment of Owen Hughes to its board of directors.
- Mr. Hughes is an accomplished life sciences executive with nearly three decades of experience in investing, operations and corporate governance.
- “We are thrilled to welcome Owen to the board of directors and leverage his experience across capital markets and pivotal business development opportunities,” said Bruce Downey, chairman of the board of directors of C4 Therapeutics.
- “I look forward to working with the board of directors and management team to capitalize on the company’s scientific prowess to the benefit of patients and shareholders alike.”